MD4516B1 - Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici - Google Patents
Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptoticiInfo
- Publication number
- MD4516B1 MD4516B1 MDA20140137A MD20140137A MD4516B1 MD 4516 B1 MD4516 B1 MD 4516B1 MD A20140137 A MDA20140137 A MD A20140137A MD 20140137 A MD20140137 A MD 20140137A MD 4516 B1 MD4516 B1 MD 4516B1
- Authority
- MD
- Moldova
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- proapoptotic agents
- thienopyrimidine derivatives
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000861 pro-apoptotic effect Effects 0.000 title abstract 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Invenţia se referă la derivaţi noi de tienopirimidină cu formula (I):în care R1, R2, R3, R4, R5, R6, R7, R12, X, A şi n au semnificaţiile definite în descriere. Invenţia se mai referă la un procedeu de preparare a acestora şi la compoziţii farmaceutice care îi conţin.Compoziţiile menţionate pot fi utilizate în calitate de agenţi proapoptotici în tratamentul cancerelor, maladiilor autoimune şi ale sistemului imun.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1363500A FR3015483B1 (fr) | 2013-12-23 | 2013-12-23 | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
Publication Number | Publication Date |
---|---|
MD20140137A2 MD20140137A2 (ro) | 2015-06-30 |
MD4516B1 true MD4516B1 (ro) | 2017-09-30 |
MD4516C1 MD4516C1 (ro) | 2018-04-30 |
Family
ID=50829005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20140137A MD4516C1 (ro) | 2013-12-23 | 2014-12-22 | Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici |
Country Status (48)
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180291373A1 (en) | 2014-10-29 | 2018-10-11 | The Walter And Eliza Hall Institute Of Medical Research | Use of therapeutic agents |
WO2016187723A1 (en) * | 2015-05-27 | 2016-12-01 | Pharmascience Inc. | Inhibitors of the tec kinase enzyme family |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
AU2017300738A1 (en) * | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
CA3030967C (en) * | 2016-07-22 | 2022-02-15 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 uses and pharmaceutical compositions thereof |
US10722466B2 (en) * | 2016-10-28 | 2020-07-28 | Les Laboratoires Servier | Liposomal formulation for use in the treatment of cancer |
EP3567043B1 (en) * | 2017-01-05 | 2023-12-06 | Henan Genuine Biotech Co., Ltd. | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer |
UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
GEP20227372B (en) * | 2017-01-06 | 2022-04-25 | Novartis Ag | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof |
EA039621B1 (ru) * | 2017-06-09 | 2022-02-17 | Ле Лаборатуар Сервье | Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции |
GEP20227357B (en) * | 2017-06-22 | 2022-02-25 | Servier Lab | Combination of mcl-1 inhibitor and standard of care treatment for hematologic cancers, uses and associated pharmaceutical compositions |
GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
JP2020531436A (ja) * | 2017-08-15 | 2020-11-05 | アッヴィ・インコーポレイテッド | 大環状mcl−1阻害剤及び使用の方法 |
WO2019035927A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
SG10202106345VA (en) * | 2017-08-15 | 2021-07-29 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
CN107573360B (zh) * | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
CN111372936B (zh) * | 2017-11-23 | 2022-12-02 | 北京赛林泰医药技术有限公司 | Mcl-1选择性抑制剂及其制备和用途 |
CN108424417B (zh) * | 2017-12-21 | 2019-09-20 | 河南真实生物科技有限公司 | 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用 |
CN110964034B (zh) * | 2018-09-29 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 |
AR116635A1 (es) | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
BR112021009050A2 (pt) * | 2018-11-14 | 2021-08-10 | Les Laboratoires Servier | combinação de um inibidor de mcl-1 e midostaurina, usos e composições farmacêuticas da mesma |
CN111187277B (zh) * | 2018-11-14 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
BR112021010072A2 (pt) * | 2018-12-06 | 2021-08-24 | Les Laboratoires Servier | Formas cristalinas de um inibidor mcl-1, processo para sua preparação e composições farmacêuticas contendo as mesmas |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
MX2021014094A (es) * | 2019-05-20 | 2022-02-11 | Novartis Ag | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso. |
AR119156A1 (es) | 2019-06-17 | 2021-11-24 | Servier Lab | Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma |
AR119494A1 (es) | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
AR119493A1 (es) | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
EP4038072A4 (en) * | 2019-10-03 | 2023-08-02 | California Institute Of Technology | MCL1 INHIBITORS AND USES THEREOF |
CN113024577B (zh) * | 2019-12-09 | 2023-06-30 | 首药控股(北京)股份有限公司 | 一种抗凋亡蛋白选择性抑制剂的制备方法 |
CN113024578A (zh) * | 2019-12-09 | 2021-06-25 | 首药控股(北京)有限公司 | 一种mcl1选择性抑制剂的多晶型物及其制备方法 |
WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | BCL-XL inhibitor antibody-drug conjugates and methods of using them |
UY39609A (es) | 2021-01-12 | 2022-08-31 | Servier Lab | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos |
EP4288434A1 (en) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
WO2022216946A1 (en) * | 2021-04-07 | 2022-10-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
AU2022290855A1 (en) | 2021-06-11 | 2023-12-07 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2024008941A1 (en) | 2022-07-08 | 2024-01-11 | Les Laboratoires Servier | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4008726A1 (de) * | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
SI1641803T1 (sl) * | 2003-06-11 | 2009-08-31 | Xention Ltd | Tienopirimidinski derivati kot inhibitorji kalijevih kanalov |
WO2005067546A2 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
US7776867B2 (en) | 2004-06-29 | 2010-08-17 | Amgen Inc. | Furanopyrimidines |
US20050288906A1 (en) | 2004-06-29 | 2005-12-29 | Drennen James K Iii | Spectroscopic pharmacy verification and inspection system |
SG156650A1 (en) * | 2004-07-16 | 2009-11-26 | Sunesis Pharmaceuticals Inc | Thienopyrimidines useful as aurora kinase inhibitors |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US7576080B2 (en) * | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2007046809A1 (en) * | 2005-10-21 | 2007-04-26 | Dow Agrosciences Llc | Thieno-pyrimidine compounds having fungicidal activity |
EP2114950B1 (en) * | 2006-12-07 | 2016-03-09 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
CA2702838A1 (en) * | 2007-10-16 | 2009-04-23 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
JP5781934B2 (ja) | 2008-11-10 | 2015-09-24 | ナショナル ヘルス リサーチ インスティテューツ | チロシンキナーゼ阻害剤としての融合2環および3環ピリミジン化合物 |
AU2011269989B2 (en) * | 2010-06-23 | 2014-12-11 | Hanmi Science Co., Ltd. | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
WO2012044993A1 (en) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders |
CN102464667B (zh) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | 一类五元杂环并嘧啶类化合物及其制备方法和用途 |
AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-12-23 FR FR1363500A patent/FR3015483B1/fr not_active Expired - Fee Related
-
2014
- 2014-12-08 JO JOP/2014/0353A patent/JO3193B1/ar active
- 2014-12-09 IL IL236143A patent/IL236143A/en active IP Right Grant
- 2014-12-10 CR CR20140569A patent/CR20140569A/es unknown
- 2014-12-10 PH PH12014000375A patent/PH12014000375A1/en unknown
- 2014-12-11 CA CA2875226A patent/CA2875226C/en active Active
- 2014-12-11 TN TN2014000516A patent/TN2014000516A1/fr unknown
- 2014-12-12 AU AU2014274644A patent/AU2014274644B2/en active Active
- 2014-12-12 AP AP2014008127A patent/AP2014008127A0/xx unknown
- 2014-12-15 DO DO2014000282A patent/DOP2014000282A/es unknown
- 2014-12-15 PE PE2014002444A patent/PE20151064A1/es active IP Right Grant
- 2014-12-17 CU CUP2014000143A patent/CU24309B1/xx unknown
- 2014-12-18 MY MYPI2014703853A patent/MY185221A/en unknown
- 2014-12-18 ZA ZA2014/09365A patent/ZA201409365B/en unknown
- 2014-12-18 CL CL2014003444A patent/CL2014003444A1/es unknown
- 2014-12-18 MX MX2014015854A patent/MX351581B/es active IP Right Grant
- 2014-12-19 JP JP2014257658A patent/JP5922215B2/ja active Active
- 2014-12-19 GE GEAP201413667A patent/GEP201706619B/en unknown
- 2014-12-19 CN CN201410800069.2A patent/CN104725397B/zh active Active
- 2014-12-19 NI NI201400150A patent/NI201400150A/es unknown
- 2014-12-19 UA UAA201413661A patent/UA120341C2/uk unknown
- 2014-12-19 US US14/576,683 patent/US9670227B2/en active Active
- 2014-12-22 RS RS20160802A patent/RS55213B1/sr unknown
- 2014-12-22 DK DK14199533.2T patent/DK2886545T3/en active
- 2014-12-22 PL PL14199533T patent/PL2886545T3/pl unknown
- 2014-12-22 MD MDA20140137A patent/MD4516C1/ro active IP Right Grant
- 2014-12-22 EA EA201401292A patent/EA029601B1/ru unknown
- 2014-12-22 SG SG10201408563UA patent/SG10201408563UA/en unknown
- 2014-12-22 ES ES14199533.2T patent/ES2594377T3/es active Active
- 2014-12-22 SI SI201430061A patent/SI2886545T1/sl unknown
- 2014-12-22 WO PCT/EP2014/078947 patent/WO2015097123A1/en active Application Filing
- 2014-12-22 TW TW103144845A patent/TWI508969B/zh active
- 2014-12-22 ME MEP-2016-207A patent/ME02521B/me unknown
- 2014-12-22 BR BR102014032336-8A patent/BR102014032336B1/pt active IP Right Grant
- 2014-12-22 EP EP14199533.2A patent/EP2886545B1/en active Active
- 2014-12-22 GT GT201400297A patent/GT201400297A/es unknown
- 2014-12-22 AR ARP140104847A patent/AR098906A1/es active IP Right Grant
- 2014-12-22 LT LTEP14199533.2T patent/LT2886545T/lt unknown
- 2014-12-22 SA SA114360144A patent/SA114360144B1/ar unknown
- 2014-12-22 RU RU2014151850/04A patent/RU2605403C2/ru active
- 2014-12-22 HU HUE14199533A patent/HUE029654T2/en unknown
- 2014-12-22 UY UY0001035915A patent/UY35915A/es active IP Right Grant
- 2014-12-22 PT PT141995332T patent/PT2886545T/pt unknown
- 2014-12-23 CO CO14282098A patent/CO7210068A1/es unknown
- 2014-12-23 KR KR1020140187349A patent/KR101636401B1/ko active IP Right Grant
-
2015
- 2015-10-28 HK HK15110667.4A patent/HK1209750A1/xx unknown
- 2015-12-16 HK HK15112389.7A patent/HK1211583A1/xx unknown
-
2016
- 2016-09-20 HR HRP20161203TT patent/HRP20161203T8/hr unknown
- 2016-09-22 CY CY20161100949T patent/CY1118058T1/el unknown
-
2017
- 2017-04-20 US US15/492,306 patent/US10278972B2/en active Active
-
2019
- 2019-03-08 US US16/296,766 patent/US20190201404A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD4516B1 (ro) | Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici | |
MD4575B1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
SA517390583B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
PH12017502246B1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
JO3674B1 (ar) | مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
SG10201804306VA (en) | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | |
MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
GEP201706704B (en) | New phosphate compounds, process for their preparation and pharmaceutical compositions containing them | |
GB201209613D0 (en) | New compounds | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MD20150048A2 (ro) | Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K | |
NZ716156A (en) | Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same | |
PH12016500034A1 (en) | New isoindoline or isoquinoline compounds, a process for their preparation and phramaceutical compositions containing them | |
IN2013CH05770A (ro) | ||
IN2013CH05769A (ro) | ||
IN2013MU02059A (ro) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued | ||
TH4A | Change/correction in patent specification |
Free format text: CHANGE OF APPLICANT ADDRESS |